EGFR Mutation Testing Practice in Advanced Non-Small Cell Lung Cancer

Lung

Volumn 192, Issue 5, 2014, Pages 759-763

  Bar, Jair ^a,i   Cyjon, Arnold ^b,i   Flex, Dov ^c,i   Sorotsky, Hadas ^d   Biran, Haim ^a,i   Dudnik, Julia ^e   Peylan Ramu, Nili ^d   Peled, Nir ^c,i   Nechushtan, Hovav ^d   Gips, Maya ^d   Katsnelson, Rivka ^d   Rosenberg, Shoshana Keren ^f   Merimsky, Ofer ^g,i   Onn, Amir ^a,i   Gottfried, Maya ^h,i  

^a SHEBA MEDICAL CENTER   (Israel)

^b ASSAF HAROFEH MEDICAL CENTER   (Israel)

^c RABIN MEDICAL CENTER   (Israel)

^d HEBREW UNIVERSITY   (Israel)

^e BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^f TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^g TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^h MEIR MEDICAL CENTER   (Israel)

ⁱ TEL AVIV UNIVERSITY   (Israel)

Author keywords

Biopsy site; Common practice; EGFR testing; Non squamous; NSCLC

Indexed keywords

VASCULOTROPIN RECEPTOR; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR;

ARTICLE; CANCER PATIENT; CLINICAL PRACTICE; GENE MUTATION; HEALTH SURVEY; HUMAN; ISRAEL; LUNG BIOPSY; MEDICAL SOCIETY; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; PULMONOLOGIST; RADIATION ONCOLOGIST; SQUAMOUS CELL LUNG CARCINOMA; SYSTEMIC THERAPY; TUMOR BIOPSY; WORK EXPERIENCE; BIOPSY; CARCINOMA, NON-SMALL-CELL LUNG; ENZYMOLOGY; GENETIC PREDISPOSITION; GENETICS; HEALTH CARE SURVEY; INTERNET; LUNG NEOPLASMS; MOLECULARLY TARGETED THERAPY; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; PERSONALIZED MEDICINE; PHENOTYPE; PREDICTIVE VALUE; QUESTIONNAIRE; TRENDS; UTILIZATION;

ANTINEOPLASTIC AGENTS; BIOPSY; CARCINOMA, NON-SMALL-CELL LUNG; DNA MUTATIONAL ANALYSIS; GENETIC PREDISPOSITION TO DISEASE; HEALTH CARE SURVEYS; HUMANS; INDIVIDUALIZED MEDICINE; INTERNET; ISRAEL; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; MUTATION; PHENOTYPE; PHYSICIAN'S PRACTICE PATTERNS; PREDICTIVE VALUE OF TESTS; QUESTIONNAIRES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84931311648     PISSN: 03412040     EISSN: 14321750     Source Type: Journal    
DOI: 10.1007/s00408-014-9604-7     Document Type: Article

References (18)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ (2007) Cancer statistics, 2007. CA Cancer J Clin 57:43–66
2. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497–1500
3. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129–2139
4. Peters S, Adjei AA, Gridelli C, Reck M, Kerr K, Felip E (2012) Metastatic non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 23(7):56–64
5. Rekhtman N, Paik PK, Arcila ME, Tafe LJ, Oxnard GR, Moreira AL, Travis WD, Zakowski MF, Kris MG, Ladanyi M (2012) Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. Clin Cancer Res 18:1167–1176
6. Hammerman PS, Sos ML, Ramos AH, Xu C, Dutt A, Zhou W, Brace LE, Woods BA, Lin W, Zhang J et al (2011) Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov 1:78–89
7. Weiss J, Sos ML, Seidel D, Peifer M, Zander T, Heuckmann JM, Ullrich RT, Menon R, Maier S, Soltermann A (2010) Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2:62ra93
8. Wang NJ, Sanborn Z, Arnett KL, Bayston LJ, Liao W, Proby CM, Leigh IM, Collisson EA, Gordon PB, Jakkula L et al (2011) Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma. Proc Natl Acad Sci USA 108:17761–17766
9. Mok T, Yang JJ, Lam KC (2013) Treating patients with EGFR-sensitizing mutations: first line or second line–is there a difference? J Clin Oncol 31:1081–1088
10. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P et al (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366:883–892
11. Yatabe Y, Matsuo K, Mitsudomi T (2011) Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma. J Clin Oncol 29:2972–2977
12. Chen ZY, Zhong WZ, Zhang XC, Su J, Yang XN, Chen ZH, Yang JJ, Zhou Q, Yan HH, An SJ et al (2012) EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas. Oncologist 17:978–985
13. Bai H, Wang Z, Chen K, Zhao J, Lee JJ, Wang S, Zhou Q, Zhuo M, Mao L, An T et al (2012) Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer. J Clin Oncol 30:3077–3083
14. Murtaza M, Dawson SJ, Tsui DW, Gale D, Forshew T, Piskorz AM, Parkinson C, Chin SF, Kingsbury Z, Wong AS et al (2013) Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 497:108–112
15. Dawson SJ, Tsui DW, Murtaza M, Biggs H, Rueda OM, Chin SF, Dunning MJ, Gale D, Forshew T, Mahler-Araujo B et al (2013) Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 368:1199–1209
16. Goto K, Ichinose Y, Ohe Y, Yamamoto N, Negoro S, Nishio K, Itoh Y, Jiang H, Duffield E, McCormack R et al (2012) Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer. J Thorac Oncol 7:115–121
17. van Gelder MM, Bretveld RW, Roeleveld N (2010) Web-based questionnaires: the future in epidemiology? Am J Epidemiol 172:1292–1298
18. Neumark Y, Lopez-Quintero C, Feldman BS, Allen AJ, Shtarkshall R (2013) Online health information seeking among Jewish and Arab adolescents in Israel: results from a National School Survey. J Health Commun 18(9):1097–1115